REGENERON

pharmaceuticals for treatment of diseases in humans and/or animals, namely diseases and/or injuries of the central and peripheral nervous systems; diseases and/or injuries to muscles; diseases and/or injuries to internal organs; and dermal cancers derived from embryonic ectodermal and mesodermal layers